首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 781 毫秒
1.
目的探讨磁共振胆胰管成像(MRCP)联合肿瘤标记物CA19-9在胆管癌中的诊断价值.方法回顾性分析26例手术及病理证实为胆管癌和22例胆道良性疾病病人的术前MRCP影像特点,并结合血清肿瘤标记物CA19-9的检测进行评价.结果 MRCP诊断的敏感性为88%,特异性为84%,阳性预测值为85%,阳性似然比为5.5;CA19-9的敏感性为82%,特异性为79%,阳性预测值为84%,阳性似然比为3.9.联合诊断的敏感性为92%,特异性为88%,阳性预测值为96%,阳性似然比为7.7.结论 MRCP联合血清CA19-9的检测,提高了对胆管癌诊断的准确性.  相似文献   

2.
探讨应用血清CA19-9诊断消化系统肿瘤的临床应用价值及应用它鉴别胰腺肿瘤与胰腺炎时的阳性参考值选定。应用酶放大化学发光免疫分析法分别检测下列人群组的血清CA19-9:对照组(21名)、消化道肿瘤组(125例,其中胰腺肿瘤患者7例)和非肿瘤组(387例,其中胰腺炎患者15例)。根据受试者工作特征曲线(ROC)分析结果并选定阳性参考值。结果表明,以18.4kU/L作阳性参考值时。该方法对消化系统肿瘤的诊断敏感性为60.8%,特异性相对于对照组和非肿瘤组分别为95.2%和68.2%:CA19-9对胰腺肿瘤的诊断敏感性为85.7%,特异性相对于对照组和非胰腺肿瘤组分别为95.0%和63.1%。胰腺肿瘤与胆道阻塞并发胰腺炎鉴别诊断的阳性参考值选取37kU/L时,其诊断特异性从13.3%提高到46.7%。这说明血清CA19-9是一项协诊消化系统肿瘤。特别是胰腺肿瘤的可靠实验室指标;提高阳性参考值,有助于鉴别胰腺肿瘤与胰腺炎。  相似文献   

3.
目的 评价部分肿瘤标志物测定联合应用探测结直肠癌术后复发、转移灶的效能.方法 研究对象为资料完整的90例结直肠癌患者.所有患者均检测血清CEA,部分患者2周内进行了CA19-9及CA242的监测.根据病理及临床随访结果,分别计算各项肿瘤标志物(单个指标、串联指标、并联指标)诊断结直肠癌术后复发及转移的灵敏度、特异性、阳性预测值、阴性预测值及准确度.结果 CEA提示结直肠癌复发及转移灶的灵敏度为74.03%、特异性为46.15%、阳性预测值为89.06%、阴性预测值为23.08%.CA19-9的灵敏度为31.88%、特异性为72.73%、阳性预测值为88.00%、阴性预测值为14.55%.CA242的灵敏度为37.50%、特异性为63.34%、阳性预测值为85.71%、阴性预测值为14.89%.肿瘤标志物指标串联结果:CEA与CA19-9,诊断效能灵敏度为26.09%、特异性为72.73%、阳性预测值为85.71%、阴性预测值为13.56%;CEA与CA242,诊断效能为灵敏度为32.81%、特异性为72.73%、阳性预测值为87.50%、阴性预测值为15.69%;CA19-9与CA242,灵敏度为25.00%、特异性为72.73%、阳性预测值为84.21%、阴性预测值为14.29%;CEA、CA19-9、CA242,灵敏度为23.44%、特异性为72.73%、阳性预测值为83.33%、阴性预测值为14.04%.指标并联结果:CEA与CA19-9并联,灵敏度为76.81%、特异性为45.45%、阳性预测值为89.83%、阴性预测值为23.81%;CEA与CA242并联,灵敏度为73.44%、特异性为36.36%、阳性预测值为87.04%、阴性预测值为19.05%;CA19-9与CA242并联,灵敏度为42.19%、特异性为63.64%、阳性预测值为87.10%、阴性预测值为15.91%;CEA、CA19-9、CA242并联后,灵敏度为78.13%、特异性为36.36%、阳性预测值为87.72%、阴性预测值为22.22%.结论 肿瘤标志物的联合应用可提升结直肠癌术后复发及转移灶的探测效能.  相似文献   

4.
CA19—9与TGF-β联检对胰腺癌的诊断价值   总被引:1,自引:0,他引:1  
目的:探讨了肿瘤标志物CA19—9与细胞因子TGF-β联检对诊断胰腺癌的临床价值。方法:采用放射免疫分析和酶联免疫双抗体法对30例胰腺癌患者进行了血清CA19—9与TGF-β测定,并与35名正常健康人作比较。结果:胰腺癌患者血清中CA19—9与TGF-β水平均非常显著的高于正常人对照组(P〈0.01)。CA19—9检测胰腺癌的敏感性为70.8%,低于TGF-β的敏感性(80.2%,P〈0.05)。两者检测胰腺癌的特异性分别为90.2%和93.4%,P〉0.05。结论:CA19—9与TGF—β诊断胰腺癌的特异性均较高,TGF-β的锸臆件高干CA19—9,两者联榆可提高胰腺痛的诊断率。  相似文献   

5.
目的 探讨血清肿瘤标志物CA19-9、CA242和CA50单项检测及联合检测在胰腺癌诊断中的应用价值.方法 选取胰腺癌患者59例(胰腺癌组)、胰腺良性疾病患者64例(胰腺良性疾病组),采用直接化学发光方法对患者血清中CA19-9、CA242、CA50水平进行检测,并比较分析单一肿瘤标志物检测及联合检测的的诊断价值.结果 胰腺癌患者血清CA19-9、CA242、CA50水平显著高于胰腺良性疾病组(P<0.05),肿瘤标志物单项检测,CA19-9敏感性最高(81.36%),CA242特异性最高(84.78%),联合检测可提高检测的敏感性(平行试验联合检测)和特异性(系列试验联合检测).结论 CA19-9、CA242、CA50的联合检测对胰腺癌的诊断提供重要参考依据,具有较高的临床价值.  相似文献   

6.
血清CA19—9、CA125、CA242、CEA联检诊断胰腺癌的临床价值   总被引:1,自引:1,他引:1  
目的:评价血清糖类抗原19—9(CA19—9),糖类抗原125(CA125),糖类抗原242(CA242)及癌胚抗原(CEA)四项指标联检对胰腺癌的诊断价值。方法:四项标志物均应用全自动化学免疫分析检测。结果:胰腺癌患者血清CA19—9、CA125、CA242、CEA水平明显高于胰腺良性病组,差异均有显著性(P〈0.01)。四项指标联检诊断胰腺癌的敏感性为91.7%,特异性92.1%。结论:血清CA19—9、CA125、CA242及CEA单项检测在胰腺癌诊断中特异性均偏低,且四项联检可提高胰腺癌的敏感性及特异性,临床诊断价值更大。  相似文献   

7.
应用组织芯片技术研究CA125和EPCAM联合检测卵巢癌的价值   总被引:1,自引:0,他引:1  
目的:构建高通量的组织芯片,评价CA125、EPCAM联合和单一检测对卵巢癌诊断的价值,探讨免疫荧光染色及激光非共聚焦方法扫描组织芯片的可行性。方法:制备卵巢组织芯片,含82例样本,其中卵巢上皮性癌52例,正常卵巢组织30例。用免疫组织化学法检测CA125和EPCAM的表达,四格表法统计出四项诊断指标值。结果:联合CA125和EP-CAM,诊断卵巢癌的特异性由86.67%上升到93.33%,阳性预测值则升至96.97%。结论:免疫荧光技术具有特异性强、敏感性高、速度快等特点,用于组织芯片染色是可行的。CA125和EPCAM的联合检测可提高特异性和阳性预测值,对卵巢癌的诊断有较高价值。  相似文献   

8.
CA50、CA19-9、CEA联检在胰腺疾病诊断中的价值   总被引:3,自引:1,他引:2  
目的 :分析CA19- 9、CEA和CA5 0在胰腺疾病诊断中的价值。方法 :4 6 9例胰腺疾病患者采用放射免疫分析测定血清CA5 0水平。采用电化学发光法测定血清CA19- 9和CEA水平。结果 :诊断胰腺癌 ,CA19- 9敏感性和特异性分别为 92 5 7%和 90 73% ;联合检测CA19- 9、CEA、CA5 0其敏感性提高为97 6 4 %。阳性诊断率为 99 16 %。结论 :采用以CA19- 9为主的肿瘤标志物联合检测 ,对胰腺疾病 ,特别是胰腺癌的诊断有着极其重要的意义。  相似文献   

9.
目的探讨血清鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、糖链抗原125(CA125)、糖链抗原199(CA19-9)联合检测在宫颈癌和宫颈癌前病变(CIN)鉴别诊断中的应用价值。方法回顾性分析2017年6月至2018年6月间收治36例CIN患者(CIN组)和68例宫颈癌患者(宫颈癌组)临床资料,并选取同期行健康体检者30例作为对照组。比较三组受试者血清肿瘤标志物SCCA、CEA、CA125、CA19-9水平,评估不同血清肿瘤标志物诊断宫颈癌的结果 ,绘制ROC曲线评估不同血清肿瘤标志物单独及联合检测诊断宫颈癌的效能。结果①三组SCCA、CEA、CA125、CA19-9对比,差异均有统计学意义(P<0.05);宫颈癌组SCCA、CEA、CA125、CA19-9均高于CIN组和对照组(P<0.05);CIN组SCCA、CEA、CA125、CA19-9均高于对照组(P<0.05);②SCCA、CEA、CA125、CA19-9单独诊断中,SCCA灵敏度、准确率、阳性预测值、阴性预测值及AUC均最高,CA125特异性最高;SCCA+CEA+CA125+CA19-9联合诊断的灵敏度、特异性、准确率、阳性预测值、阴性预测值及AUC均最高。结论宫颈癌、CIN和正常人群SCCA、CEA、CA125、CA19-9水平差异显著,SCCA、CEA、CA125、CA19-9联合诊断宫颈癌具有较高的诊断效能。  相似文献   

10.
肿瘤标志物的敏感性和特异性是评价肿瘤标志物的两个重要指标。CA19-9已广泛应用于消化道肿瘤特别是胰腺癌、胆管癌的诊断、疗效监测及复发和预后的预测,尤其是肝胆管结石是否合并胆管癌变的鉴别。但在实际工作中,一些胆道良性疾病如肝胆管结石的患者,血清CA19-9有明显或不同程度的增高,假阳性率较高。为此,我们选择2005年1月至2010年8月间CA19-9阳性的肝胆管结石住院患者110例,并选择同期经手术和病理证实为肝胆管结石并胆管癌(HCWC)的患者40例,将其血清CA19-9含量与30名健康人作对照,现报道如下。  相似文献   

11.
评价肿瘤标志物与MRCP联合对肝外胆道梗阻的鉴别诊断价值.采用化学发光免疫分析法测定97例肝 外胆道梗阻患者血清CA19-9、CA125及CEA水平,行MRCP显像并进行统计分析.CA19-9在恶性梗阻时的阳 性率明显高于CEA和CA125(P<0.01),与MRCP联合检查,诊断准确性可达100%.血清CA19-9检测与 MRCP结合鉴别诊断肝外胆道梗阻不仅能提供精确的定位信息,而且可以进行准确的定性判断;CEA和CA125 还可以为恶性梗阻的腹腔转移提供可靠信息.  相似文献   

12.
目的 探讨糖类抗原用名的错误方式,以便达到规范用名的目的.方法 使用万方数据库对所研究的用名进行检索.结果 发现糖类抗原125(CA125)误写成CA12-5、CA-125、CA125和Ca125,错误率(%)分别为1.27、11.32、0.17和0.06;CA15-3误写成CA-153、CA153、CA153和Ca153,错误率(%)分别为4.03、62.86、0.50和0.17;CA19-9误写成CA-199、CA199、CA199、CA19-9和Ca199,错误率(%)分别为5.36、46.66、0.06、0.06和0.06;CA242误写成CA-242、CA24-2和CA242,错误率(%)分别为3.74、3.06和0.34;CA50误写成CA-50,错误率(%)为13.43;CA72-4误写成CA-724和CA724,错误率(%)分别为1.42和44.76.结论 糖类抗原缩写用名较混乱,希望能规范用名.  相似文献   

13.
We conducted a study to evaluate cancer associated antigen CA-50 and CA 19-9 as tumor markers of gynecological malignancies. The positive rates of CA-50 and CA 19-9 for ovarian cancer were 35.5% and 48.8%, respectively, and thus were not very high. In terms of histological typing, relatively high positive rates were noted in mucinous type-42.9% for CA-50 and 71.4% for CA 19-9. Both antigens showed high false positive rates for benign ovarian tumors, especially for dermoid cyst, but produced few false positive cases of endometrial cyst. For cervical cancer and endometrial cancer, these antigens were positive at low rate. In conclusion, the present evaluation indicated that both CA-50 and CA 19-9 do not necessarily suffice as screening markers for gynecological malignancies; that they could potentially be of help for diagnosis of ovarian cancer of mucinous type; and that their false positive rates for endometrial cyst were very low.  相似文献   

14.
Tumor associated carbohydrate antigen TAC-41 identified by the monoclonal antibody against a gastric adenocarcinoma cell line. We evaluated the serum levels of TAC-41 in 55 patients with various malignancies and 44 patients with benign diseases, and compared them with the serum levels of other tumor markers including CA 19-9 and CA-50. When the normal range of serum TAC-41 level was less than 40 dilution titer, the positive rate for malignancies of TAC-41 was 100% in pancreas cancer, 80% in biliary tract cancer and 87% in hepatocellular carcinoma. On the other hand, specificity (64%) of TAC-41 in all patients was less than that of other tumor markers. However, efficiency (68%) of TAC-41 was no less than those of other tumor markers. Comparison of the serum levels of TAC-41 with CA 19-9 or CA-50 in the same samples revealed a highly positive correlation (r = 0.891) in patients with various cancers. These results indicate that TAC-41 is clinically no less useful than CA 19-9 or CA-50 as a tumor marker. The usefulness of this method is characterized by its short turnaround time and lower cost than other tumor markers. Eventually, TAC-41 is one of the most useful tumor marker in mass screening for digestive malignant diseases.  相似文献   

15.
Serum CA 50 was determined by a time resolved fluorometric immunoassay (TR-FIA) with CANAG CA-50 DELFIA kit. Evaluation of the assay system gave satisfactory results in its sensitivity, accuracy, reproducibility, dynamic range and easy handling. No prozone phenomenon was observed up to 347,000 U/ml. From a histogram of 134 normal sera, the cut off point was determined at 34 U/ml. CA 50 in 202 patients' sera was determined with this assay. Nineteen of 20 patients pancreatic cancer, 6 of 21 gastric cancer, 14 of 25 hepatoma gave positive values. In comparison with CA 19-9, higher values and higher rates of positive CA 50 were observed in benign and malignant liver diseases, suggesting its non-cancerous origin in the liver. A high correlation was observed between the level of CA 50 and CA 19-9 of 157 patients' sera. Serum CA 50 was completely correlated with CA 19-9 in the clinical course of patients with pancreatic cancer, but not in patients with hepatoma. Thus we conclude that the CANAG CA-50 DELFIA System is useful for the diagnosis and monitoring cancer patients but must be used with care because of its elevation in benign liver diseases.  相似文献   

16.
Serum CA 19-9 antigen concentrations were measured in 246 patients with benign and histologically confirmed malignant gastrointestinal diseases. The CA 19-9 concentration was above the upper limit of the normal range (0-37 U/ml) in 76% of patients with pancreatic carcinoma, 73% of patients with cholangiocarcinoma, 42% of patients with gastric carcinoma, and 22% of patients with hepatoma. High CA 19-9 concentrations were found mainly in patients with a metastasised cancer, whereas 71% of patients with a localised carcinoma had normal CA 19-9 concentrations. All of the patients with benign gastric diseases had normal CA 19-9 values. Moderately increased concentrations were found in 15-36% of the patients with benign pancreatic, liver, and biliary tract diseases. alpha-fetoprotein was a better marker for hepatomas than CA 19-9. CA 19-9 was better than carcinoembryonic antigen in differentiating malignant from benign diseases. The results indicate that the CA 19-9 assay is not completely specific for cancer but serves as a valuable adjunct, especially in the diagnosis of pancreatic carcinoma.  相似文献   

17.
为提高原发性肝癌的诊断率和与肝硬化,其他慢性肝病的鉴别诊断,本文采用放射免疫分析法和免疫放射分析法。对50例健康体检者、48例原发性肝癌、39例肝硬化,36例其他一肝病患者,分别检验其血清中甲胎蛋白,糖类抗原19-9肿瘤标志物的含量,结果进行比较。  相似文献   

18.
目的:探讨可溶性B7-H4(soluble B7-H4,sB7-H4)在早期胃癌中的诊断价值。方法:应用酶联免疫吸附试验(ELISA)夹心法检测80例早期胃癌患者与50例正常人血清sB7-H4水平,用化学发光法检测血清CEA、CA19-9水平,利用受试者工作特性曲线(ROC),比较分析sB7-H4作为早期胃癌血清标志物的诊断价值。结果:早期胃癌患者血清sB7-H4水平(47.61±13.57)ng/ml明显高于正常人(30.62±8.65)ng/ml,差异有统计学意义(P<0.01)。sB7-H4在早期胃癌诊断中的灵敏度(81.25%)和准确性(78.46%)均高于CEA及CA19-9,特异性(74%)低于CEA及A199。结论:sB7-H4在早期胃癌诊断中具有良好的临床应用前景,联合检测sB7-H4、CEA和CA19-9可提高胃癌的诊断率。  相似文献   

19.
目的:研究糖类抗原CA50、CA19-9、CA242联检对胰腺癌及结、直肠癌患者的临床诊断价值.方法:应用免疫放射分析(IRMA)检测136例胰腺癌及结、直肠癌患者血清CA50、CA19-9、CA242的含量.结果:胰腺癌患者CA50、CA19-9、CA242单检阳性率分别为66.67%、74.07%、81.48%,三项联检阳性率为94.44%.结、直肠癌患者CA50、CA19-9、CA242单检阳性率分别为60.98%、53.66%、42.68%,三项联检阳性率为82.93%.结论:为了早期诊断胰腺癌及结、直肠癌,应联检CA50、CA19-9、CA242三种肿瘤标志物,以提高检出的阳性率.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号